Corporate

Besides private funding, Biohope has secured over €7 million in public funds to develop its products for renal transplantation and rheumatoid arthritis. We have been awarded the SME Instrument H2020 program grant (phases 1 and 2, 2015-16), the CDTI-European Seal of Excellence through the EIC Accelerator Program (2022), the CAM grant to support the growth of innovative technology-based SMEs (2023), and the CAM-European Seal of Excellence through the EIC Accelerator Program (2024).

In addition, our innovative personalized medicine projects for patients with autoimmune diseases and transplants received funding from the EIB through a €15 million ‘venture debt’ financing agreement, signed in 2023. This agreement is backed by the InvestEU program.

The BEI financing agreement with Biohope is part of the InvestEU program’s focus on research, innovation, and digitalization, areas where the company excels at the European level. The funding aims to support Biohope’s international expansion, the launch of its first kidney transplant product, and the development of its pipeline of personalized and precision medicine products for chronic autoimmune diseases. The total project cost is estimated at €34 million.